Thrombin purification
The invention relates to thrombin compositions with reduced levels of high molecular weight impurities. In particular, the levels of factor Va, prions and/or viral agents are greatly reduced. Ts invention also relates generally to methods for the preparation of thrombin having a high degree of purity and high specific activity. More specifically, the invention encompasses steps to exclude high molecular weight impurities from thrombin preparations by size exclusion filtration. In additional embodiments, the preparation of thrombin additionally includes an ion exchange filtration step. The methods of the invention are particularly suited for large scale purification of thrombin. This invention also relates generally to stabilized formulations containing thrombin cormpositions. More specifically, the present invention relates to stabilized, liquid formulations containing thrombin having a high degree of purity and high specific activity and methods of making and using such formulations.
1 . A method for preparing purified thrombin, the method comprising:
(a) applying a thrombin preparation to a size exclusion filter capable of excluding impurities that have a molecular weight greater than 40 kDa; and
(b) recovering the purified thrombin.
2 . The method of claim 1 , wherein the size exclusion filter is capable of excluding impurities that have molecular weights ranging from 40 kDa to 300 kDa.
3 . The method of claim 1 , wherein impurities in the recovered purified thrombin are reduced by at least 50%.
4 . The method of claim 1 , wherein impurities in the recovered purified thrombin are reduced by at least 80%.
5 . The method of claim 1 , wherein the specific activity of the recovered purified thrombin is increased by at least 1000%.
6 . The method of claim 1 , wherein the specific activity of the recovered purified thrombin is increased by at least 1500%.
7 . The method of claim 1 , wherein the recovered purified thrombin is substantially free of impurities.
8 . The method of claim 1 , wherein the recovered purified thrombin is substantially free of factor Va.
9 . The method of claim 1 , wherein the recovered purified thrombin is substantially free of prions.
10 . The method of claim 1 , wherein the recovered purified thrombin has a prion reduction equal to at least 3.5 logs.
11 . The method of claim 1 , wherein the recovered.purified thrombin is substantially free of viral agents.
12 . The method of claim 1 , wherein the recovered purified thrombin is substantially pure.
13 . A thrombin composition substantially free of impurities.
14 . A thrombin composition substantially free of factor Va.
15 . The thrombin composition of claim 15 , wherein the factor Va is less than 0.4 μg/1000 units of thrombin.
16 . A thrombin composition substantially free of viral agents, wherein the log reduction value is greater than 3.5 per virus.
17 . A thrombin composition having a thrombin specific activity between about 1800 and 3000 u/mg of protein.
18 . The method of claim 1 further comprising lowering the pH below about 5 of the thrombin preparation.
19 . The method of claim 1 further comprising applying electromagnetic radiation to the thrombin preparation.
20 . A method for preparing a thrombin having enhanced purity, the method comprising:
(a) applying the thrombin preparation to a chromatographic purification step;
(b) applying the thrombin preparation to a size exclusion filter;
(c) applying the thrombin preparation to an ion exchange filter; and
(d) recovering the purified thrombin.
21 . A stabilized liquid thrombin formulation comprising a thrombin composition wherein the thrombin composition is substantially free of impurities and at least one excipient.
22 . The stabilized liquid thrombin formulation of claim 21 where in the formulation maintains at least 60% of its initial potency for up to two years.
23 . The stabilized liquid thrombin formulation of claim 21 where in the formulation maintains at least 70% of its label claim potency for up to two years.
24 . A stabilized liquid thrombin formulation comprising:
a thrombin composition wherein the thrombin composition is substantially free of impurities;
glycerol;
polyethylene glycol;
sodium chloride;
sodium acetate; and
wherein the formulation has a pH of between 6-8.
25 . A method of administering the stabilized thrombin formulation of claim 21 , the method comprising administering the stabilized thrombin formulation topically.
26 . A method of administering the stabilized thrombin formulation of claim 21 , the method comprising:
drawing the thrombin formulation into a syringe;
forcing the thrombin formulation through the syringe; and
flooding the surface of a body lumen with the thrombin formulation.
27 . A method of administering the stabilized thrombin formulation of claim 21 , the method comprising spraying the thrombin formulation on to the surface of a body lumen.
28 . A method of administering the stabilized thrombin formulation of claim 21 , the method comprising:
saturating a sponge with the thrombin formulation; and
applying the sponge to the surface of a body lumen.
29 . A kit comprising:
the stabilized thrombin formulation of claim 21;
a vial capable of containing the thrombin formulation; and
a needle.
30 . A kit comprising:
the stabilized thrombin formulation of claim 21; and
a device that is capable of spraying the thrombin formulation.
31 . A stabilized liquid thrombin formulation comprising:
thrombin;
glycerol;
polyethylene glycol;
sodium chloride;
sodium acetate; and
wherein the formulation has a pH of between 6-8.
32 . The stabilized liquid thrombin formulation of claim 31 where in the formulation maintains at least 60% of its initial potency for up to two years.
33 . The stabilized liquid thrombin formulation of claim 31 where in the formulation maintains at least 70% of its initial label potency for up to two years.